Our Board of Directors is a interdisciplinary, accomplished team of senior leaders, healthcare experts, top executives, entrepreneurs, academics, and service providers. Our Directors share a passion and commitment to CHI’s mission of making the world a healthier place through research, education, communication, training, symposia, and reports. The Board sets our strategy, maintains our direction, ensures our initiatives are executed, ensures we are adequately funded, keeps CHI true to our mission of public service, and ensures we are in compliance with rules of administration and governance.

.

Michael Rosen, MBA (Chairman)
Managing Director of Rosen Bioscience Strategies & Adjunct Professor at Northwestern University
Mr. Michael Rosen, MBA is a global life science connector with expertise in building global businesses (from a start-up phase beginning with university technology licensing) and life science clusters. Mr. Rosen has lived in 6 Latin American countries, 3 European countries, and Japan. He has extensive work experience in Europe, Latin America, Asia, Israel, and Canada. He is a developer of science parks with world-class universities with extensive experience in creating entrepreneurial faculty and identifying key areas of scientific expertise to attract international companies to co-locate at the university and commence activities in the U.S. Market. He is also actively engaged with city/state governments to attract foreign direct investment in companies co-locating at these science parks and universities. Michael was the Senior Vice President, New Business Development for the Science + Technology Group at Forest City Enterprises, a NYSE-traded real estate development company which develops and builds bioscience parks across the US. Mr. Rosen works with key research universities affiliated with Forest City bioparks, such as Northwestern University in Chicago, and endeavors to bring life science companies from Europe, Asia, Latin America, India, Israel and Canada into these parks. During his thirty-five years in the life sciences industry, he held management positions with Pfizer, Bristol-Myers Squibb, and Searle/Monsanto while living in Japan, Latin America, and Europe and worked extensively in Canada, Israel and Asia. Mr. Rosen has been President/CEO of European and US biotech and medical device companies; additionally he founded Rosen Bioscience Management to provide CEO services to start-up life science companies including a University of Wisconsin diagnostics company developing biomarkers for kidney disease, a University of Illinois company developing new cancer vaccines and a wound-care company from Michael Reese Hospital. Mr. Rosen is a founder, former Vice-Chairman and current board member of the Illinois Biotechnology Industry Organization (IBIO). In addition to IBIO, Mr. Rosen is a member of the board and Senior Vice-President of the America-Israel Chamber of Commerce Chicago and co-chairs its Life Science Practice Group. In this capacity, he has led several Illinois bioscience trade missions to Israel over the last 10 years and established relationships between Illinois and the Israeli Research University and life science communities. He is a member of the Industry Advisory Board for Northwestern University’s Masters of Biotechnology Program as well as Professor of International Management and Marketing at Lake Forest Graduate School of Management where he has led their annual program in Brazil for the last 8 years. He received his Bachelor of Arts in Sociology and International Relations from Beloit College and an MBA in International Business from the University of Miami. He has post-graduate studies at Northwestern University, Sophia University (Tokyo, Japan) and Universidad Tecnica Federico Santa Maria (Santiago, Chile).
Biography
LinkedIn
Julius Pryor III (Vice Chairman)
Author and Expert in Innovation, Diversity, & Inclusion
Mr. Julius Pryor III is a strategist, author, keynote speaker, and diversity and inclusion expert. He is the former Head of Innovation, Diversity & Inclusion at Genentech, a member of the Roche Group. Genentech is a biotechnology company, dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Julius considers Diversity & Inclusion strategic force multipliers that drive innovation. He’s held executive-level jobs at Johnson & Johnson (J&J), Coca-Cola Enterprises (CCE), Russell Athletic, Abbott Labs and Takeda Pharmaceuticals. He was Vice President of Global Diversity at both J&J and CCE. Julius is a U.S. Navy Captain (Retired), Surface Warfare Officer and Instructor for the Navy Officer Leadership Development Program. He’s held numerous leadership roles in the Navy up to and including, Unit Commanding Officer and Fleet Staff Officer. He was in the re-commissioning crew of the USS Missouri (BB-63) and is one of a select few to have served as an active duty Battleship Turret Officer. Julius’ recently published his first book: Thriving in a Disruptive World: 6 Critical Concepts for Navigating the 21st Century. “In a time of disruption, there are huge opportunities.” Julius is a graduate of Morehouse College and The Williston Northampton School. While at Morehouse, he was initiated into Psi Chapter of the Omega Psi Phi Fraternity.
Biography
WebsiteLinkedIn
Dr. James Gillespie, PhD, JD, MPA (President)
Co-Founder & President of CHI
Dr. James J. Gillespie, PhD, JD, MPA, is a researcher and scholar, with an expertise focusing on the strategy of the life sciences sectors. Dr. Gillespie is also CEO of the Chicago Life Sciences Consortium, a resource for early and middle stage biotechnology, medical device, and healthcare companies in the metropolitan Chicago area. He is Co-Leader of the Working Group on Innovation & Interoperability (WGII), a healthcare analytics project featuring executives from Blue Cross Blue Shield Association, Computer Sciences Corporation, Healthcare Information and Management Systems Society, Metropolitan Chicago Healthcare Council, and Walgreens Corporation. The WGII aims to leverage large claims, clinical, and prescription databases for analytics to improve healthcare quality, access, and out-comes. Dr. Gillespie chairs the annual symposium “Emerging Markets in Life Sciences Symposium: The Role of Relationships” hosted by Microsoft Corporation and co-sponsored by Pharmaceutical Executive Magazine. He founded and chairs the annual symposium “Diversity, Inclusion, & Life Sciences”, which has become the top annual event focused specifically on the interface between diversity, inclusion, and the global life sciences industry. Dr. Gillespie’s research has appeared in Academy of Management Review, American Behavioral Scientist, European Journal of Social Psychology, Federal Reserve Bank, Harvard Business Review, and Strategic Management Journal. His education includes Northwestern University Kellogg School of Management, M.A., Ph.D.; Harvard University School of Law, J.D.; Princeton University Woodrow Wilson School of Public Policy, M.P.A.; Massachusetts Institute of Technology, B.S.; and Carnegie Mellon University.
Biography
LinkedIn
Dr. Cheryl Beal Anderson, PharmD, MBA
Vice President & Head of Regulatory Affairs at Upsher-Smith Laboratories
Dr. Cheryl Beal Anderson, PharmD, MBA, is Senior Director, Global Regulatory Affairs at Lundbeck, a global CNS pharmaceutical company committed to making progress in mind and developing innovative treatment for Psychiatric and Neurologic diseases. The corporate headquarters are located in Valby, Denmark and US Offices in Deerfield, IL. Anderson leverages 20 + year career experience and knowledge in NDA/BLA, ANDA, FDA negotiations, FDA Advisory Committee experience to support the company’s vision to expand capabilities needed to obtain new drug approvals in the United States with an inclusive and collaborative leadership style with teams based in Valby, Denmark. Anderson leads the US regulatory strategy for registration, co-leadership for the Global Regulatory Response Team and Regulatory Filing Team. Externally, Anderson is the Lundbeck representative on multiple PhRMA LD-KITs (FDA Patient Focused Drug Development, Benefit: Risk Assessment, REMS and Adaptive Clinical Trial Design) and the DIA-HBA Leadership Project Steering Committee. Prior to Lundbeck, Anderson was Senior Director/Senior Fellow/Associate Director, U.S. Regulatory Affairs at Eli Lilly and Co. in Indianapolis, IN. Anderson led regulatory strategy staff for the Oncology, Cardiovascular, Autoimmune therapeutic areas and Pharmacogenomics and was the regulatory strategy lead on various product development teams. While at Lilly, she was the pharma Co-Chair with FDA that led to the publication of FDA Draft Guidance entitled, “Target Product Profile – A strategic development process tool” in 2007. Anderson also worked in Regulatory Affairs for Pfizer Global R&D, Parke-Davis and Alcon Laboratories. Prior to her pharmaceutical industry career, Anderson held full-time assistant professor positions at University of Texas College of Pharmacy (Austin, Texas) and University of Illinois at Chicago College of Pharmacy (Chicago, Illinois). Anderson was nominated for the Women and High Tech 2014 Leading Light ‘You Inspire Us! Award for demonstrating success in inspiring women in science, technology, and/or engineering to look beyond their own horizons. Anderson is also the recipient of the Center for Leadership Development, Business Award (Indianapolis, IN). Anderson holds professional membership in the Drug Information Association, Regulatory Affairs Professional Society, Healthcare Businesswomen’s Association (HBA) and International Society of Clinical Trial Management. Anderson is a member of the Executive Advisory Board, HBA Indiana Chapter and past president of the HBA Indiana chapter. She is a lifetime member of Jack and Jill of America and served on the National Executive Board as National Program Director, 2010-2012. Anderson is pursuing a Pharmaceutical and Healthcare Marketing MBA from the Haub School of Business, Saint Joseph’s University in Philadelphia, PA. Anderson completed undergraduate degrees in Biomedical Science from Texas A&M University (College Station, Texas) and Pharmacy at University of Texas (Austin, Texas). Anderson earned a post-graduate PharmD degree from the University of Texas at Austin and the University of Texas Health Science Center in San Antonio, followed by a one-year post-doctoral clinical pharmacy residency in psychiatric practice at San Antonio State Hospital (San Antonio, Texas).
Biography
LinkedIn
Dr. Benée Brown, PharmD
Senior Medical Liaison at Sanofi
Dr. Benée Brown, PharmD, is a graduate of the University of Texas and the University of Texas Health Science Center in San Antonio with experience in hospital, ambulatory care, managed care, and prescription benefit management (PBM) settings. Prior to her Diabetes Medical Liaison role with Sanofi, she served as a Women’s Health Medical Science Liaison with Eli Lilly. This was followed by serving as a Formulary Pharmacist for the second largest Prescription Benefit Management (PBM) Company in the U.S., with responsibility for more than 8 million covered lives. As a PBM pharmacist for the Caremark/CVS National Pharmacy and Therapeutics (P&T) Committee, Benée carefully conducted clinical reviews, pharmacoeconomic evaluations and provided evidence-based recommendations for various categories and classes of Federal Drug Administration (FDA) approved prescription drugs evaluation by the National Caremark/CVS P&T Committee Benée joined Sanofi in 2005 as a U.S. Medical Affairs Diabetes Medical Liaison in Chicago, IL and Austin, Texas in 2015. She serves as a respected leader and regional partner through the provision of evidence-based solutions in the form of diabetes-related education, support of diabetes-related clinical research and provision of unsolicited medical information. In addition, Benée works in establishing new and strengthening existing relationships with key diabetes thought-leaders, private and public organizations, and institutions. Benée has also successfully led initiatives and projects related to innovation, organizational strategy, diversity & inclusion, and the advancement of improved operational processes. Since 2012, Benée has also served as an adjunct clinical professor at Chicago State University College of Pharmacy. Benée is an avid runner, biker, swimmer, reader and traveler. She enjoys sharing her active lifestyle with her wonderful family which includes her husband, daughter and son.
Biography
Lynn Hanessian
Chief Science Strategist at Edelman
Ms. Lynn Hanessian is Chief Science Strategist within Edelman’s Health practice, dedicated to science engagement and communication. She brings over 20 years of health and medical communications strategy leadership into every client engagement. Her ability to bring together industry, content and media expertise to galvanize ideas, strategies and programming for clients leads the industry. Lynn’s recent client work has included Merck, Optimer Pharmaceuticals, Jazz Pharmaceuticals, University Hospitals, Otsuka, Rehabilitation Institute of Chicago, Millennium: The Takeda Oncology Company, and American Medical Association. Prior, Lynn served as chief executive officer of Zeno Group and general manager for the Edelman health team in Chicago. A passionate patient advocate, Hanessian is board member and chair of the research, advocacy and public policy committee for the Asthma and Allergy Foundation of America and serves on the President’s Council of the Cancer Support Community. Lynn earned an AB in economics from the University of Chicago
Biography
LinkedInTwitter
Joff Masukawa
President at Diligentia
Mr. Joff Masukawa is President of Diligentia, LLC, a life sciences consultancy that develops commercial business strategies, product value narratives, and tactical commercialization requirements for manufacturers of Rare Orphan and Specialty Drugs, Cell and Gene Therapy, and other novel emerging medical innovations. Diligentia can also lead strategy implementation for small organizations and offers complete government affairs capability. Prior to founding Diligentia, Joff was Vice President and Global Head of Government Relations and Public Affairs at Shire, where he designed and led strategies to build the company’s brand, leadership, and engagement with governments, patients, payers, and other key external stakeholders. Joff has held leadership roles across commercial functions including market access and distribution, pricing and reimbursement, advocacy and government affairs, and sales and marketing at Shire, Genzyme, Visible Genetics, Gentiva, and LabCorp. He has led and executed many launch strategies for first-in-class products and services, and he is an expert at enabling optimal legislative, regulatory, and market access environments to support business objectives. He began as a clinical sales representative for Merck. Joff is an adjunct instructor at the George Washington School of Medicine and Health Sciences in the Department of Clinical Research and Leadership. He also serves on the Board of Directors of Caregiver Action Network and the Center for Healthcare Innovation. He holds a BA in international studies from Johns Hopkins University and completed his graduate work in international affairs at the Johns Hopkins School of International Studies and in strategic communications at Columbia University.
Biography
LinkedIn
Stephen Morales, MBA
Senior Manager at L.E.K. Consulting
Stephen Morales is a Senior Manager at L.E.K. Consulting. Prior to his current role, he was a Director with the Life Science Practice at Navigant. Stephen has more than 16 years of experience in the medical device and pharmaceutical industries. He began his healthcare career as an engineer, designing and manufacturing medical devices. Most recently, as part of Merck and Schering Plough, Stephen successfully launched several cardiovascular, women’s health and OTC products across three continents for a range of organizations. Prior to Merck and Schering-Plough, Stephen worked in medical device companies where he led cross-functional teams to develop cutting edge cardiovascular and neurovascular devices through PMA, IDE, 510(k) and CE mark regulatory pathways. Most recently, he was based in emerging markets to expand drug and device programs in markets across Asia, including China and India. In his tenure, he has developed several programs and relationships with Key Opinion Leaders on issues related to expanding access to care and early stage product commercialization. He brings his analytical approach and his global expertise in strategic marketing, product development, new market penetration and thought leadership to Navigant’s clients.He received his MBA from Duke’s Fuqua School of Business with a concentration in health sector management and his engineering degree from MIT.
Biography
WebsiteLinkedIn
Dr. Linda Scarazzini, RPh, MD
Vice President of Pharmacovigilance & Patient Safety at AbbVie
Dr. Linda Scarazzini is the Vice President of Pharmacovigilance and Patient Safety at AbbVie. She was formerly Vice President of Medical Safety Evaluation at AbbVie. Dr. Scarazzini has worked in the pharmaceutical industry for 16 years. In 2016, she was selected by her industry peers to serve as the Biopharma Representative on FDA Drug Safety and Risk Management Advisory Committee. Before joining AbbVie, Dr. Scarazzini served as the Director of the Division of Pharmacovigilance in the Office of Pharmacovigilance and Epidemiology at the FDA’s Center for Drug Evaluation and Research (CDER). She began her career in pharmacovigilance at Sanofi-Aventis, rising to the level of Associate Vice President of Pharmacovigilance and Risk Management. Board-certified in Internal Medicine, Dr. Scarazzini was Chief Medical Resident at The Graduate Hospital of the University of Pennsylvania. She graduated Summa Cum Laude with a pharmacy degree from Philadelphia College of Pharmacy and Science. She has co-authored several publications on post-marketing signal evaluation and risk management. In addition to presentations at industry meetings such as Drug Information Association, she frequently presents on leadership. She is a 1994 graduate of Temple University School of Medicine.
Biography
Marquise Stillwell, MBA
Founder and Principal of Openbox
Mr. Marquise Stillwell is the Founder and Principal of Openbox. As a business designer and developer for more than two decades, he grounds the Openbox vision in strategic planning from the fields of investing, product development, and technology. Marquise also works in creative leadership, teaching with the KaosPilots in Denmark and South Africa to help students learn by doing. An active supporter of the arts, Marquise has collaborated with director Petter Ringbom on three short films and one feature-length movie, Shield and Spear (2014), about the rise of creative expression in post-apartheid South Africa. Marquise acts as a board member for the Lowline Underground Park and board advisor for the Andrew Goodman Foundation and MoCADA, and he is a mentor to Geeks Without Bounds and the Girls & Boys Club. He is also a supporter of the Joyce Theater, Makeshift Magazine and MCA Denver for their ability to inspire exploration and empower creative cultures. Marquise is passionate about the power of design and has a boundless curiosity for life. You can find him riding his bike through the streets of Manhattan, doing his part to build a greener urban future.
Biography
WebsiteLinkedInTwitter
Douglas Swill, JD, LLM
Attorney & Chair of the Health Care Practice Group at Drinker Biddle
Mr. Douglas B. Swill, JD, is the Chair of the Drinker Biddle Health Care Practice Group and a member of the firm’s Management Committee. His practice is concentrated in the representation of health systems, hospitals and medical groups throughout the United States. He counsels clients on a variety of health care transactional and regulatory matters, including affiliations, mergers, acquisitions, governance and non-profit issues, Stark and Anti-Kickback Laws, and federal tax-exemption matters. Additionally, he advises clients on health care reform, Medicare and Medicaid audits, coverage and overpayment issues, compliance programs, quality of care audits, voluntary disclosures, due diligence reviews, and contract projects. Doug’s 25 years of experience also includes advising health systems on physician integration and compensation strategies, including the associated health care regulatory risks, licensure, certification and reimbursement matters. Prior to joining the firm in 1993, he was an assistant state’s attorney in Chicago and practiced in the Office of the State’s Attorney’s Federal Litigation and Hospitals Departments. In that capacity, Doug represented Cook County Hospital in general counsel matters and Cook County officials in federal litigation matters that included oral arguments before the U.S. Court of Appeals for the Seventh Circuit. Doug is consistently recognized by Chambers USA, Leading Lawyers — Illinois and Illinois Super Lawyers, Best Lawyers in America, and has been selected by his peers for inclusion in The Best Lawyers in America, as well as named one of the country’s “Outstanding Physician Practice Lawyers” by Nightingale’s Healthcare News.
Biography
WebsiteLinkedIn
Michel Feldman, JD (Chairman Emeritus)
Retired Partner at Seyfarth Shaw
Mr. Michel Feldman, JD, has over 40 years of experience in complex corporate transactions and concentrates his practice on the representation of numerous individuals, families, trusts, and public and private corporations across a wide range of industries including pharmaceuticals, medical devices, computer software, entertainment, manufacturing, distribution, and retail. Mr. Feldman is a frequent lecturer and author on mergers and acquisitions, capital raising and corporate governance issues. Among his accomplishments, Mr. Feldman has counseled a NYSE pharmaceutical company regarding start-up financing, venture capital, two public offerings, various mergers with public and private companies, and licensing, distribution and acquisition agreements with domestic and foreign companies, and served as its interim General Counsel for nine months. He has also structured and assisted with the planning, negotiation and financing of transactions involving management buy outs and merger and acquisitions ranging from $1 million to $1 billion, including Special Purpose Acquisition (SPAC) transactions. Mr. Feldman's education includes J.D., Northwestern University School of Law (1968); Order of the Coif, Editorial Board, Northwestern Law Review, B.S./B.A., Northwestern University (1965), Honorable Mention for National Elijah Watt Sells CPA Award.
Biography
WebsiteLinkedIn Email